NASDAQ$CAPR
Capricor Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Capricor reported financial results for the first quarter of 2024 and provided a corporate update.
Capricor Therapeutics reported revenue of $4.9 million and a net loss of $9.8 million for the first quarter of 2024. The company received a $10 million milestone payment under its U.S. Distribution and Commercialization Agreement with Nippon Shinyaku.
- Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy fully enrolled and on track to report top-line data in Q4 2024.
- Positive Type-B CMC FDA Meeting held in Q1; Company aligned with FDA on demonstration of non-clinical comparability.
- Received First Milestone Payment of $10 Million under U.S. Distribution and Commercialization Agreement with Nippon Shinyaku in Q1.
- Recent FDA Feedback Supports Requests for a Pre-BLA Meeting and Subsequent Rolling BLA Submission at Upcoming Type-B Clinical FDA Meeting in May 2024.
Headline financials
Revenue & EPS history
Capricor · Revenue · Quarterly
$4.91M
Forward guidance
Capricor anticipates several milestones, including a Type-B clinical FDA meeting in May 2024, reporting 3-year HOPE-2 OLE data in Q2 2024, and topline data from HOPE-3 (Cohort A) in Q4 2024. They expect cash, cash equivalents and marketable securities will be sufficient to cover anticipated expenses and capital requirements into the first quarter of 2025.
Tailwinds
- Type-B clinical FDA meeting in May 2024 to discuss requests for a pre-BLA meeting and rolling BLA schedule.
- Plan to report 3-year HOPE-2 OLE data in the second quarter of 2024.
- Plan to announce further updates with respect to next steps for HOPE-3 (Cohort B), when available.
- Plan to report topline data from HOPE-3 (Cohort A) in the fourth quarter of 2024.
- Updates on NIAID collaboration for StealthX™ vaccine as they become available; NIAID plans to initiate Phase 1 clinical trial in late 2024, subject to regulatory approval.
Headwinds
- Expectation excludes potential milestone payments under Commercialization and Distribution Agreements with Nippon Shinyaku.
- Excludes strategic use of capital not currently in the Company’s base-case planning assumptions.
- R&D expenses increased from $7.66 million to $11.10 million compared to last year
- General and administrative expenses increased from $3.50 million to $4.07 million compared to last year
- Net loss increased from $7.76 million to $9.79 million compared to last year
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-0.8%
Avg return
Earnings day
-1.3%
Avg return
5 days after
+7.6%
Avg return
30 days after
39%
19 / 49 earnings
Positive
+25.4%
Q2 2023
Best reaction
-20.4%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.5% | -10.9% | — | |
| Q4 2025 | +1.0% | -7.5% | -6.6% | |
| Q3 2025 | +10.8% | +0.7% | +388.8% | |
| Q1 2025 | +10.0% | +15.0% | +31.1% | |
| Q4 2024 | +17.5% | +10.3% | -7.9% | |
| Q3 2024 | +2.2% | +1.5% | -26.7% | |
| Q2 2024 | -0.8% | +0.3% | +4.3% | |
| Q1 2024 | -1.9% | +17.0% | -4.5% | |
| Q4 2023 | +5.5% | +14.5% | +56.8% | |
| Q3 2023 | +13.0% | +7.0% | +49.3% | |
| Q2 2023 | +25.4% | +32.2% | +32.6% | |
| Q1 2023 | -1.2% | +3.9% | +15.2% | |
| Q4 2022 | -1.7% | -3.4% | -5.6% | |
| Q3 2022 | -3.4% | -13.2% | -19.1% | |
| Q2 2022 | +14.5% | +6.1% | +28.0% | |
| Q1 2022 | -5.4% | -1.9% | +28.2% | |
| Q4 2021 | -8.1% | -9.0% | -22.9% | |
| Q3 2021 | -4.6% | -6.0% | -13.0% | |
| Q2 2021 | -8.4% | -10.0% | +11.1% | |
| Q1 2021 | +6.8% | +13.6% | +31.3% | |
| Q4 2020 | -4.8% | -11.4% | -19.3% | |
| Q3 2020 | -7.2% | -9.0% | -10.4% | |
| Q2 2020 | -20.4% | -18.0% | -42.3% | |
| Q1 2020 | -10.1% | -18.9% | -33.3% | |
| Q4 2019 | +0.9% | -0.9% | +34.2% | |
| Q3 2019 | -14.1% | -25.0% | -48.0% | |
| Q2 2019 | -9.3% | -23.6% | -34.2% | |
| Q1 2019 | -2.4% | -23.8% | -10.7% | |
| Q4 2018 | -16.1% | +14.3% | -10.7% | |
| Q3 2018 | -4.3% | -1.1% | -40.9% | |
| Q2 2018 | -8.3% | -15.0% | -5.0% | |
| Q1 2018 | -2.2% | -3.0% | -6.0% | |
| Q4 2017 | +2.8% | -0.6% | -11.7% | |
| Q3 2017 | +10.5% | +37.5% | -11.5% | |
| Q2 2017 | -7.1% | -6.2% | -8.8% | |
| Q1 2017 | -13.8% | -21.6% | -33.6% | |
| Q4 2016 | +8.0% | +3.3% | +5.0% | |
| Q3 2016 | -2.5% | +7.5% | -4.3% | |
| Q2 2016 | +4.0% | +4.0% | +10.8% | |
| Q1 2016 | +2.1% | — | — | |
| Q4 2015 | +4.0% | — | — | |
| Q1 2012 | -4.3% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +4.5% | — | — | |
| Q1 2011 | -13.8% | — | — | |
| Q4 2010 | -3.2% | — | — | |
| Q3 2010 | -13.2% | — | — | |
| Q2 2010 | +18.4% | — | — | |
| Q1 2010 | -3.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro